Avastin use extended

The licence for Avastin (bevacizumab) has been extended to include use in combination with paclitaxel for first-line treatment of patients with metastatic breast cancer.

Previously, bevacizumab was licensed for use in combination with intravenous 5-fluorouracil, folinic acid and irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Avastin must be administered under the supervision of a physician experienced in the use of antineoplastic products.

Further information: Roche 01707 366000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more